Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Abstract Hormone receptor HR-positive/HER2-negative (HR+/HER2−) breast cancer is the most common subtype in China, representing 60–70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven...

Full description

Saved in:
Bibliographic Details
Main Authors: Caifeng Jia, Sen Zhang, Jie Wang, Bing Feng, Fenghao Shi, Meiqi Wang, Sainan Li, Hao Xu, Mingxia Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
CDK4/6 inhibitors
Fulvestrant
Cost-effectiveness
HR-positive/HER2-negative
Breast cancer
China
Online Access:https://doi.org/10.1038/s41598-025-97504-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-97504-3

Similar Items